Evidence map›Paper›PMID 41659682›Full record

ArticlebioRxiv : the preprint server for biology2026

Gene-centered representation of coding and regulatory variation enables outcome prediction.

Ksenia Sokolova, Vessela N Kristensen, Christopher Y Park, Chandra Theesfeld, Laura Mariani, Matthias Kretzler, Olga G Troyanskaya, Cure Glomerulonephropathy (CureGN) Study Consortium

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ksenia SokolovaPrinceton Precision Health, Princeton University, Princeton, NJ, USA.ORCID 0000-0001-7499-5387
Vessela N KristensenInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
Christopher Y ParkFlatiron Institute, Simons Foundation, New York City, NY, USA.
Chandra TheesfeldLewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ, USA.ORCID 0000-0002-8379-6600
Laura MarianiUniversity of Michigan, Michigan Medicine, Ann Arbor, MI, USA.
Matthias KretzlerUniversity of Michigan, Michigan Medicine, Ann Arbor, MI, USA.ORCID 0000-0003-4064-0582
Olga G TroyanskayaPrinceton Precision Health, Princeton University, Princeton, NJ, USA.ORCID 0000-0002-5676-5737
Cure Glomerulonephropathy (CureGN) Study Consortium

Funding

CureGNU24DK100845 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CRYSTAL A. GADEGBEKU, Laura H Mariani · 2019 to 2026
$12.1M
KPMP Kidney Mapping and Atlas Project (KMAP)U01DK133090 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jonathan Himmelfarb, Matthias Kretzler · 2022 to 2026
$10.4M
The Columbia PCC for CureGN: the Cure Glomerulonephropathy networkU01DK100876 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Andrew Stephen Bomback, ALI G GHARAVI · 2019 to 2026
$8.5M
CureGN-Penn PCCU01DK100846 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI LAWRENCE B. HOLZMAN · 2019 to 2026
$8.3M
CUREGN 3.0 - Pediatric Nephrology Consortium - PCCU01DK100866 · NIDDK · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI Laurence A Greenbaum, Jon Klein · 2019 to 2026
$7.7M
CureGN-3: UNCPCCU01DK100867 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Vimal Kumar Derebail, Ronald J Falk · 2019 to 2026
$6.7M
lntegration and Visualization of Diverse Biological DataR01GM071966 · NIGMS · PRINCETON UNIVERSITY · PI TROYANSKAYA, OLGA G · 2005 to 2022
$6.4M
Genomics of glomerular diseaseRC2DK116690 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI KIRYLUK, KRZYSZTOF, KRETZLER, MATTHIAS · 2018 to 2022
$5.0M
NIDDK NIH HHS RC2 DK116690NIDDK NIH HHS U01 DK100846NIDDK NIH HHS U01 DK100866NIDDK NIH HHS U01 DK100867NIDDK NIH HHS U01 DK100876NIDDK NIH HHS U01 DK133090NIDDK NIH HHS U24 DK100845NIGMS NIH HHS R01 GM071966
6 · The paper itself

Abstract

Integrating coding and regulatory variation into unified, interpretable representations remains a challenge in functional genomics. Current approaches either focus on common variants or analyze individual variants in isolation, missing the cumulative, cell-type-specific impact of both coding and noncoding variants on each gene. We present Volaria, a computational framework that integrates coding and regulatory genetic variation into unified, gene-centered representations for disease outcome prediction from whole-genome sequencing. Volaria leverages deep learning models to capture variant effects on cell-type-specific gene expression and integrates them with AI-predicted exonic variant pathogenicity to produce representations that capture the cumulative effect of genome-wide rare and common variation. Applied to whole genomes of individuals with rare glomerular diseases, Volaria predicts individual outcomes directly from germline sequence, demonstrating that structured, cell-type-aware representations capture predictive signals beyond population-based polygenic risk scores and unstructured representations. Importantly, the framework identifies context-specific biological mechanisms, providing interpretability that can be aligned with clinical measurements. By encoding genome-wide variation into compact and biologically grounded representations, Volaria provides a scalable foundation for genome interpretation and individualized outcome modeling from germline sequence, complementing phenotypic and clinical information in the future integrative frameworks.

Indexed as

clinical outcomesdisease progressionfunctional genomicsgene expressiongenomic embeddingskidney diseasemachine learningrare diseaseregulatory variantswhole-genome sequencing

Identifiers

PMID41659682
PMCPMC12873896

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.